Vonoprazan (Voquenza) is a potassium-competitive acid blocker (PCAB) approved by the FDA to treat gastroesophageal reflux disease (GERD), specifically for healing erosive esophagitis and relieving related heartburn in adults.
It is also used in combination with antibiotics to treat H. pylori infections.
As a novel acid-suppressing medication, it works within 2-3 hours to reduce stomach acid and can be taken with or without food.
It heals all grades of erosive esophagitis (EE), maintains healing of EE, relieves symptoms of non-erosive GERD, and treats H. pylori (combined with amoxicillin and/or clarithromycin).
Dosage & Administration
Typically taken once daily (20 mg for healing, 10 mg for maintenance/non-erosive).
Tablets should be swallowed whole, with or without food.
Mechanism: Unlike PPIs, vonoprazan (a PCAB) binds to potassium in the stomach, blocking proton pumps to stop acid production for 24 hours.
Common side effects include diarrhea, abdominal pain, nausea, and upper respiratory tract infections.
Long-term use may increase risks of low magnesium, low vitamin B12 and bone fractures.
Used for the shortest duration necessary to minimize potential risks like fundic gland polyps.
Liver/Kidney Disease: Dosage adjustments may be required for those with severe impairment.